Seven cases consolidated into a class action against AstraZeneca Pharmaceuticals L.P. and several other pharmaceutical companies were transferred into the District of Delaware on Oct. 29, largely on the grounds of saving time and money.

U.S. District Chief Judge Colleen McMahon of the Southern District of New York, wrote in her Aug. 12 order granting the transfer that the deciding factor in moving the antitrust class action, filed by employee benefit funds as end-payor plaintiffs, was that it should be held in the same venue as another class action alleging nearly identical offenses against the same group of companies.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]